Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid

Human Gene Therapy

Volumn 11, Issue 12, 2000, Pages 1657-1669

  Blackwell, Jerry L ^a,b   Hui, Li ^a,c   Gomez Navarro, Jesus ^a,c   Dmitriev, Igor ^a   Krasnykh, Victor ^a   Richter, Christy A ^b   Shaw, Denise R ^c   Alvarez, Ronald D ^a   Curiel, David T ^a   Strong, Theresa V ^a,c,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Kentucky   (United States)

^c University of Alabama at Birmingham   (United States)

^d Division of Hematology/Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY;

ADENOCARCINOMA; ADENOVIRUS; ARTICLE; ASCITES; ASCITES FLUID; CELL CULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; IN VITRO STUDY; METHODOLOGY; OVARY TUMOR; PATHOLOGY; PLANT GROWTH; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOVIRIDAE; ANTIBODIES; ASCITES; ASCITIC FLUID; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; OVARIAN NEOPLASMS; TROPISM; TUMOR CELLS, CULTURED;

EID: 0034632348     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050111313     Document Type: Article

References (62)

1. ALI, M., LEMOINE, N.R., and RING, C.J. (1994). The use of DNA viruses as vectors for gene therapy. Gene Ther. 1, 367-384.
2. ALVAREZ, R.D., and CURIEL, D.T. (1997). A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients. Hum. Gene Ther. 8, 229-242.
3. ALVAREZ, R.D., BARNES, M.N., GOMEZ-NAVARRO, J., WANG, M., STRONG, T.V., ARAFAT, W., ARANI, R.B., JOHNSON, M.R., ROBERTS, B.L., SIEGAL, G.P., and CURIEL, D.T. (2000). A cancer gene therapy approach utilizing an anti-erbB-2 single chain antibody (sFv) encoding adenovirus (AD21): A phase I trial. Clin. Cancer Res. (in press).
4. ANONYMOUS (1999). Human gene marker/therapy clinical protocols. Hum. Gene Ther. 10, 1043-1092.
5. BEHBAKHT, K., BENJAMIN, I., CHIU, H.C., ECK, S.L., VAN DEERLIN, P.G., RUBIN, S.C., and BOYD, J. (1996). Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. Am. J. Obstet. Gynecol. 175, 1260-1265.
6. BENJAMIN, I., and RUBIN, S.C. (1998). Modern treatment options in epithelial ovarian carcinoma. Curr. Opin. Obstet. Gynecol. 10, 29-32.
7. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURT-JONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
8. BILBAO, G., GOMEZ-NAVARRO, J., and CURIEL, D.T. (1998). Targeted adenoviral vectors for cancer gene therapy. Adv. Exp. Med. Biol. 451, 365-374.
9. BLACKWELL, J.L., MILLER, C.R., DOUGLAS, J.T., LI, H., REYNOLDS, P.N., CARROLL, W.R., PETERS, G.E., STRONG, T.V., and CURIEL, D.T. (1999). Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 125, 856-863.
10. CLAYMAN, G.L., EL-NAGGAR, A.K., LIPPMAN, S.M., HENDERSON, Y.C., FREDERICK, M., MERRITT, J.A., ZUMSTEIN, L.A., TIMMONS, T.M., LIU, T.J., GINSBERG, L., ROTH, J.A., HONG, W.K., BRUSO, P., and GOEPFERT, H. (1998). Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232.
11. COLCHER, D., MILENIC, D.E., FERRONI, P., ROSELLI, M., and SCHLOM, J. (1991). In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72. Int. J. Radiat. Appl. Instrument. [B] 18, 395-401.
12. DESHANE, J., SIEGAL, G.P., ALVAREZ, R.D., WANG, M.H., FENG, M., CABRERA, G., LIU, T., KAY, M., and CURIEL, D.T. (1995). Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. 96, 2980-2989.
13. DESHANE, J., SIEGAL, G.P., WANG, M., WRIGHT, M., BUCY, R.P., ALVAREZ, R.D., and CURIEL, D.T. (1997). Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynecol. Oncol. 64, 378-385.
14. DMITRIEV, I., KRASNYKH, V., MILLER, C.R., WANG, M., KASHENTSEVA, E., MIKHEEVA, G., BELOUSOVA, N., and CURIEL, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713.
15. DOUGLAS, J.T., ROGERS, B.E., ROSENFELD, M.E., MICHAEL, S.I., FENG, M., and CURIEL, D.T. (1996). Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotechnol. 14, 1574-1578.
16. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91, 6196-6200.
17. GAHERY-SEGARD, H., JUILLARD, V., GASTON, J., LENGAGNE, R., PAVIRANI, A., BOULANGER, P., and GUILLET, J.G. (1997a). Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus-induced Ig subclass shifts. Eur. J. Immunol. 27, 653-659.
18. GAHERY-SEGARD, H., MOLINIER-FRENKEL, V., LE BOULAIRE, C., SAULNIER, P., OPOLON, P., LENGAGNE, R., GAUTIER, E., LE CESNE, A., ZITVOGEL, L., VENET, A., SCHATZ, C., COURTNEY, M., LE CHEVALIER, T. TURSZ, T., GUILLET, J.G., and FARACE, F. (1997b). Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Clin. Invest. 100, 2218-2226.
19. GAHERY-SEGARD, H., FARACE, F., GODFRIN, D., GASTON, J., LENGAGNE, R., TURSZ, T., BOULANGER, P., and GUILLET, J.G. (1998). Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72, 2388-2397.
20. GOLDMAN, C.K., ROGERS, B.E., DOUGLAS, J.T., SOSNOWSKI, B.A., YING, W., SIEGAL, G.P., BAIRD, A., CAMPAIN, J.A., and CURIEL, D.T. (1997). Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 57, 1447-1451.
21. GRAHAM, F., and PREVEC, L. (1991). Manipulation of adenovirus vectors. In Molecular Biology: Gene Transfer and Expression Techniques, Vol. 7. E.J. Murray and J.M. Walker, eds. (Humana Press, Clinton, NJ) pp. 109-128.
22. HARVEY, B.G., HACKETT, N.R., EL-SAWY, T., ROSENGART, T.K., HIRSCHOWITZ, E.A., LIEBERMAN, M.D., LESSER, M.L., and CRYSTAL, R.G. (1999). Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol. 73, 6729-6742.
23. HERZ, J., and GERARD, R.D. (1993). Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. U.S.A. 90, 2812-2816.
24. HIDAKA, C., MILANO, E., LEOPOLD, P.L., BERGELSON, J.M., HACKETT, N.R., FINBERG, R.W., WICKHAM, T.J., KOVESDI, I., ROELVINK, P., and CRYSTAL, R.G. (1999). CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J. Clin. Invest. 103, 579-587.
25. HUNG, M.C., MATIN, A., ZHANG, Y., XING, X., SORGI, F., HUANG, L., and YU, D. (1995). HER-2/neu-targeting gene therapy - a review. Gene 159, 65-71.
26. JOOSS, K., YANG, Y., and WILSON, J.M. (1996). Cyclophosphami de diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum. Gene Ther. 7, 1555-1566.
27. JOOSS, K., TURKA, L.A., and WILSON, J.M. (1998). Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 5, 309-319.
28. KAFRI, T., MORGAN, D., KRAHL, T., SARVETNICK, N., SHERMAN, L., and VERMA, I. (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 95, 11377-11382.
29. KAPLAN, J.M., and SMITH, A.E. (1997). Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum. Gene Ther. 8, 1095-1104.
30. KASONO, K., BLACKWELL, J.L., DOUGLAS, J.T., DMITRIEV, I., STRONG, T.V., REYNOLDS, P., KROPF, D.A., CARROLL, W.R., PETERS, G.E., BUCY, R.P., CURIEL, D.T., and KRASNYKH, V. (1999). Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin. Cancer Res. 5, 2571-2579.
31. KAY, M.A., MEUSE, L., GOWN, A.M., LINSLEY, P., HOLLENBAUGH, D., ARUFFO, A., OCHS, H.D., and WILSON, C.B. (1997). Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc. Natl. Acad. Sci. U.S.A. 94, 4686-4691.
32. KOLLS, J.K., LEI, D., ODOM, G., NELSON, S., SUMMER, W.R., GERBER, M.A., and SHELLITO, J.E. (1996). Use of transient CD4 lymphocyte depletion to prolong transgene expression of El-deleted adenoviral vectors. Hum. Gene Ther. 7, 489-497.
33. LAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227, 680-685.
34. LANDIS, S.H., MURRAY, T., BOLDEN, S., and WINGO, P.A. (1998). Cancer statistics, 1998. CA Cancer J Clin 48, 6-29.
35. LEI, D., LEHMANN, M., SHELLITO, J.E., NELSON, S., SIEGLING, A., VOLK, H.D., and KOLLS, J.K. (1996). Nondepleting anti-CD4 antibody treatment prolongs lung-directed El-deleted adenovirus-mediated gene expression in rats. Hum. Gene Ther. 7, 2273-2279.
36. MACK, C.A., SONG, W.R., CARPENTER, H., WICKHAM, T.J., KOVESDI, I., HARVEY, B.G., MAGOVERN, C.J., ISOM, O.W., ROSENGART, T., FALCK-PEDERSEN, E., HACKETT, N.R., CRYSTAL, R.G., and MASTRANGELI, A. (1997). Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8, 99-109.
37. MARGULIES, D.H. (1993). Antibody detection and preparation. In Current Protocols in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, eds. (John Wiley & Sons, New York).
38. McGUIRE, W.P., HOSKINS, W.J., BRADY, M.F., KUCERA, P.R., PARTRIDGE, E.E., LOOK, K.Y., CLARKE-PEARSON, D.L., and DAVIDSON, M. (1996). Cyclophospham ide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1-6. [See comments]
39. MILLER, C.R., BUCHSBAUM, D.J., REYNOLDS, P.N., DOUGLAS, J.T., GILLESPIE, G.Y., MAYO, M.S., RABEN, D., and CURIEL, D.T. (1998). Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58, 5738-5748.
40. MILLIKEN, G.A., and JOHNSON, D.E. (1992). Analysis of Messy Data, Volume I: Designed Experiments. (Chapman & Hall, New York).
41. MOLNAR-KIMBER, K.L., STERMAN, D.H., CHANG, M., KANG, E.H., ElBASH, M., LANUTI, M., ELSHAMI, A., GELFAND, K., WILSON, J.M., KAISER, L.R., and ALBELDA, S.M. (1998). Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9, 2121-2133.
42. MORSY, M.A., GU, M., MOTZEL, S., ZHAO, J., LIN, J., SU, Q., ALLEN, H., FRANLIN, L., PARKS, R.J., GRAHAM, F.L., KOCHANEK, S., BETT, A.J., and CASKEY, C.T. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95, 7866-7871.
43. MUJOO, K., MANEVAL, D.C., ANDERSON, S.C., and GUTTERMAN, J.U. (1996). Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12, 1617-1623.
44. RANCOURT, C., ROGERS, B.E., SOSNOWSKI, B.A., WANG, M., PICHE, A., PIERCE, G.F., ALVAREZ, R.D., SIEGAL, G.P., DOUGLAS, J.T., and CURIEL, D.T. (1998). Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 4, 2455-2461.
45. ROSENBERG, S.A., ZHAI, Y., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., SEIPP, C.A., EINHORN, J.H., ROBERTS, B., and WHITE, D.E. (1998). Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90, 1894-1900.
46. ROSENFELD, M.E., WANG, M., SIEGAL, G.P., ALVAREZ, R.D., MIKHEEVA, G., KRASNYKH, V., and CURIEL, D.T. (1996). Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J. Mol. Med. 74, 455-462.
47. ROTHER, R.P., SQUINTO, S.P., MASON, J.M., and ROLLINS, S.A. (1995). Protection of retroviral vector particles in human blood through complement inhibition. Hum. Gene Ther. 6, 429-435.
48. RUOSLAHTI, E. (1996). RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697-715.
49. RUOSLAHTI, E., and PIERSCHBACHER, M.D. (1987). New perspectives in cell adhesion: RGD and integrins. Science 238, 491-497.
50. SCHULICK, A.H., VASSALLI, G., DUNN, P.F., DONG, G., RADE, J.J., ZAMARRON, C., and DICHEK, D.A. (1997). Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J. Clin. Invest. 90, 209-219.
51. STERMAN, D.H., TREAT, J., LITZKY, L.A., AMIN, K.M., COONROD, L., MOLNAR-KIMBER, K., RECIO, A., KNOX, L., WILSON, J.M., ALBELDA, S.M., and KAISER, L.R. (1998). Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9, 1083-1092.
52. TAIT, D.L., OBERMILLER, P.S., JENSEN, R.A., and HOLT, J.T. (1998). Ovarian cancer gene therapy. Hematol. Oncol. Clin. North Am. 12, 539-552.
53. TAKEUCHI, Y., COSSET, F.L., LACHMANN, P.J., OKADA, H., WEISS, R.A., and COLLINS, M.K. (1994). Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68, 8001-8007.
54. TOMKO, R.P., XU, R., and PHILIPSON, L. (1997). HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U.S.A. 94, 3352-3356.
55. TONG, X.W., BLOCK, A., CHEN, S.H., CONTANT, C.F., AGOULNIK, I., BLANKENBURG, K., KAUFMAN, R.H., WOO, S.L., and KIEBACK, D.G. (1996). In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol. Oncol. 61, 175-179.
56. UKKONEN, P., HOVI, T., VON BONSDORFF, C.H., SAIKKU, P., and PENTTINEN, K. (1984). Age-specific prevalence of complement-fixing antibodies to sixteen viral antigens: A computer analysis of 58,500 patients covering a period of eight years. J. Med. Virol. 13, 131-148.
57. VANDERKWAAK, T.J., WANG, M., GOMEZ-NAVARRO, J., RANCOURT, C., DMITRIEV, I., KRASNYKH, V., BARNES, M., SIEGAL, G.P., ALVAREZ, R.D., and CURIEL, D.T. (1999). An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol. Oncol. 74, 227-234.
58. WANG, Q., GREENBURG, G., BUNCH, D., FARSON, D., and FINER, M.H. (1997). Persistent transgene expression in mouse liver following in vivo gene transfer with a delta El/delta E4 adenovirus vector. Gene Ther. 4, 393-400.
59. WOHLFART, C. (1988). Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62, 2321-2328.
60. WOHLFART, C.E., SVENSSON, U.K., and EVERITT, E. (1985). Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera. J. Virol. 56, 896-903.
61. WORGALL, S., LEOPOLD, P.L., WOLFF, G., FERRIS, B., VAN ROIJEN, N., and CRYSTAL, R.G. (1997a). Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum. Gene Ther. 8, 1675-1684.
62. WORGALL, S., WOLFF, G., FALCK-PEDERSEN, E., and CRYSTAL, R.G. (1997b). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 37-44.